Rivastigmine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Rivastigmine: From Alzheimer's Disease to Glaucoma
One-Sentence Summary
Rivastigmine is a cholinesterase inhibitor originally used in Alzheimer's and Parkinson's disease dementia. The TxGNN model predicts it may also lower intraocular pressure and be useful in Glaucoma, but this is currently supported only by 0 clinical trials and 3 preclinical/review publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer's disease dementia (based on known drug class; not verified in the current regulatory data pack) |
| Predicted New Indication | Glaucoma |
| TxGNN Prediction Score | 99.27% |
| Evidence Level | L4 (preclinical/mechanistic evidence only) |
| Norway Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, rivastigmine is a carbamate-type acetylcholinesterase (and butyrylcholinesterase) inhibitor, originally developed to increase cholinergic transmission in Alzheimer's and Parkinson's disease dementia.
Cholinergic signaling via muscarinic (M3) receptors in the anterior eye segment is known to regulate aqueous humor outflow through the trabecular meshwork, and non-selective AChE inhibitors are established hypotensive agents in the eye. This provides a plausible mechanistic bridge between rivastigmine's central cholinergic activity and a potential ocular hypotensive effect.
This link is directly supported by an early animal study showing that topical rivastigmine lowered intraocular pressure in rabbits, alongside more recent reviews of cholinergic agents and AChE inhibitor chemistry relevant to glaucoma. However, all available evidence is preclinical or narrative-review in nature — there is no human clinical trial data confirming this repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10673128 | 2000 | Animal study (preclinical) | J Ocul Pharmacol Ther | Topical rivastigmine, a selective AChE inhibitor, lowered intraocular pressure in normotensive rabbits over an 8-hour monitoring period |
| 39130374 | 2024 | Review | Front Mol Biosci | Reviews cholinergic (muscarinic) regulation of IOP via the trabecular meshwork and limitations of current M3 agonists, framing rationale for cholinergic IOP-lowering agents |
| 27967267 | 2017 | Review (patent literature) | Expert Opin Ther Pat | Reviews AChE inhibitors/reactivators, noting mild AChE inhibition has therapeutic relevance in Alzheimer's disease, myasthenia gravis, and glaucoma |
Norway Market Information
Rivastigmine currently holds no marketing authorization in Norway (0 licenses on record); no product/dosage form data is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The glaucoma signal rests on a single 25-year-old animal study plus two narrative reviews — no human clinical trials, no confirmed MOA data, and the drug is not currently marketed in Norway. Evidence is too preliminary to support progression.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank or equivalent source
- TFDA/Norway-equivalent regulatory label (warnings, contraindications) — currently a Blocking data gap (DG001)
- At least one human proof-of-concept study (e.g., ocular formulation safety/IOP-lowering trial)
- Formal ophthalmic route/formulation compatibility assessment, since current approved formulations are oral/transdermal, not ocular
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.